✦ LIBER ✦

Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C

✍ Scribed by Lindsay Mollison; Leanne Totten; James Flexman; Miles Beaman; Robert Batey

Book ID: 108950801
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 97 KB
Volume: 21
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.2006.04320.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preliminary report of a randomized, doub

Preliminary report of a randomized, double-blind placebo-controlled trial of a Chinese herbal medicine preparation CH-100 in the treatment of chronic hepatitis C

✍ RG BATEY; A BENSOUSSAN; YANG YI FAN; S BOLLIPO; MA HOSSAIN 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C

✍ Hideki Ueno; Tosiya Sato; Seiichiro Yamamoto; Katsuaki Tanaka; Shinichi Ohkawa; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB

Filtration leukocytapheresis therapy in

Filtration leukocytapheresis therapy in rheumatoid arthritis: A randomized, double-blind, placebo-controlled trial

✍ Toshihiko Hidaka; Kimihiro Suzuki; Yasunori Matsuki; Mitsuyo Takamizawa-Matsumot 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 2 views

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONT

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PSEUDOEPHEDRINE IN CORYZA

✍ Jenny Latte; David Taverner; Peter Slobodian; Sepehr Shakib 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

A Double-Blind, Randomized, Placebo-Cont

A Double-Blind, Randomized, Placebo-Controlled Trial of Macrolide in the Treatment of Chronic Rhinosinusitis

✍ Ben Wallwork; William Coman; Alan Mackay-Sim; Lennart Greiff; Anders Cervin 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Combination therapy with thymosin α1 and

Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: A randomized, placebo-controlled double-blind trial

✍ Kenneth E. Sherman; Maria Sjogren; Robin L. Creager; Melissa A. Damiano; Stephen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB 👁 1 views

Hepatitis C is a major cause of liver disease leading to cirrhosis. Although interferon (IFN) is the only approved therapy, treatment is characterized by low response rates and dose-limiting side effects. We evaluated the addition of thymosin ␣1 (TA1), an immunomodulatory peptide, to the standard tr